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Abstract
Background: Increased serum levels of homocysteine and uric acid have each been associated with cardiovascular
risk. We analyzed whether homocysteine and uric acid were associated with glomerular filtration rate (GFR) and
albuminuria independently of each other. We also investigated the association of MTHFR polymorphisms related to
homocysteine with albuminuria to get further insight into causality.
Methods: This was a cross-sectional population-based study in Caucasians (n = 5913). Hyperhomocysteinemia was
defined as total serum homocysteine ≥ 15 μmol/L. Albuminuria was defined as urinary albumin-to-creatinine ratio
> 30 mg/g.
Results: Uric acid was associated positively with homocysteine (r = 0.246 in men and r = 0.287 in women, P <
0.001). The prevalence of albuminuria increased across increasing homocysteine categories (from 6.4% to 17.3% in
subjects with normal GFR and from 3.5% to 14.5% in those with reduced GFR, P for trend < 0.005).
Hyperhomocysteinemia (OR = 2.22, 95% confidence interval: 1.60-3.08, P < 0.001) and elevated serum uric acid (OR
= 1.27, 1.08-1.50, per 100 μmol/L, P = 0.004) were significantly associated with albuminuria, independently of
hypertension and type 2 diabetes. The 2-fold higher risk of albuminuria associated with hyperhomocysteinemia
was similar to the risk associated with hypertension or diabetes. MTHFR alleles related to higher homocysteine
were associated with increased risk of albuminuria.
Conclusions: In the general adult population, elevated serum homocysteine and uric acid were associated with
albuminuria independently of each other and of renal function.
Background
Homocysteine, a sulfur containing amino acid involved
in methionine metabolism, is a potential atherogenic
molecule and is considered as an independent risk fac-
tor for cardiovascular disease (CVD) [1-3]. Serum levels
of total homocysteine (tHcy) are elevated in patients
with chronic kidney disease (CKD) and, more generally,
in patients with reduced renal function [1,4]. Several
studies have shown that elevated tHcy levels are asso-
ciated with atherothrombotic disease in coronary, cere-
bral and peripheral arteries [3,5]. A similar phenotype is
associated with CKD [6,7]. Similar pathological changes
are observed in glomerular injury and tHcy-induced vas-
cular damages, such as endothelial dysfunction, cell pro-
liferation, increased oxidative stress and prothrombotic
state [8,9]. As a consequence, high tHcy levels may
potentially induce renal injury via direct action on kid-
ney cells, rather than only result as a consequence of
impaired renal function. In other words, tHcy could be
involved as a cause of renal atherosclerosis and renal
damage, leading to a vicious cycle with accelerated dete-
rioration of renal function.
To date, tHcy has been associated with microalbumi-
nuria in population-based studies [1,10,11] and in diabetic
patients [10,12,13]. The population-based Hoorn study,
which included subjects aged 50 to 75 years, found that
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baseline tHcy was associated with microalbuminuria not
only at baseline [10], but also after a mean follow-up of
6.1 years, independently of renal function [11]. In the
National Health and Nutrition Examination Survey 1991-
1994, the largest population-based study available so far
(3387 subjects aged ≥ 40 years), elevated tHcy was asso-
ciated with albuminuria independently of vitamin B status
[1]. However, it remains unclear whether tHcy causes
albuminuria or is merely the consequence of reduced
renal function, which is itself reflected by albuminuria
[14]. As albuminuria is an established marker of kidney
damage in diabetic and nondiabetic individuals and a
strong predictor of cardiovascular morbidity and mortality
[15,16], a better understanding of the determinants of
albuminuria is therefore of great interest.
Serum uric acid (SUA) is associated with increased risk
of incident kidney disease [17], and it also predicts mor-
tality in patients with CKD [18]. Several studies have
shown a link between SUA concentrations and tHcy
[19,20]. The extent to which tHcy and SUA may inde-
pendently influence renal function and renal damage is
not known. Although the association of renal function
and tHcy levels is well-known in selected clinical samples
[21], only few large scale population-based data have
been published so far [1,10]. To our knowledge none of
the latter investigated the role of SUA in this context.
The aim of this study was to evaluate the association
between elevated tHcy and the presence of impaired
renal function, expressed as either decreased glomerular
filtration rate (GFR) or albuminuria in a large popula-
tion-based sample in Switzerland. We also investigated
the potential modifying effect of SUA on these relation-
ships. In order to evaluate whether the association
between tHcy and albuminuria could be causal, we
looked at the association between albuminuria and the
methylenetetrahydrofolate reductase (MTHFR) gene
polymorphisms strongly correlated with tHcy.
Methods
Study population
The CoLaus Study has been described previously [22].
Briefly, a simple non-stratified random sample of 35% of
the overall population of the city of Lausanne, Switzer-
land, aged 35-75 years (n = 56,694) was drawn. Inclu-
sion criteria were: a) written informed consent; b) age
between 35 and 75 years; c) Caucasian origin. Out of
the 6188 participants, we excluded 145 subjects because
of various missing values, leaving 5913 subjects for the
present analysis.
The study was approved by the ethical committee of
the Faculty of Medicine of the University of Lausanne
(Switzerland) and the research conformed to the Hel-
sinki Declaration. All participants provided written
informed consent.
Assessment process and data collection
Participants attended the outpatient clinic of the Univer-
sity Hospital Center of Lausanne (CHUV) in the morn-
ing after an overnight fast. BMI was defined as weight
in kilograms divided by height in meters squared (kg/
m2). Blood pressure was measured three times on the
left arm using a clinically validated automatic oscillo-
metric device [23]Hypertension was defined as a mean
systolic blood pressure ≥ 140 mmHg and/or a diastolic
blood pressure ≥ 90 mmHg and/or presence of antihy-
pertensive drug treatment.
Biological data
A venous blood sample (50 ml) was collected from each
participant under fasting conditions. The analytical pro-
cedures for biological markers and clinical chemistry
methods have been described previously [22]. Hyperho-
mocysteinemia was defined as a tHcy level ≥ 15 μmol/L
[1]. Diabetes was defined as a fasting blood glucose ≥ 7
mmol/l and/or presence of any antidiabetic drug
(including insulin).
A spot urine sample was collected for the assessment
of urinary creatinine and albumin, and the ACR was cal-
culated. Albuminuria was defined as a value of ACR
above 30 mg/g, which includes microalbuminuria (ACR
30-300 mg/g) and macroalbuminuria (ACR > 300 mg/g)
[24]. Glomerular filtration rate (GFR) was estimated by
the simplified MDRD prediction equation: GFR (ml/
min/1.73 m2) = 186 × (SCr)
-1.154 × (Age)-0.203 × (0.742 if
female), where SCr is serum creatinine concentration in
mg/dL and age is in years [25]. We also conducted sen-
sitivity analyses using the Cockcroft-Gault formula to
estimate creatinine clearance (CCr): CCr = (140 - age) ×
(weight)/72 × SCr x (0.83 if female), where SCr is in mg/
dL, weight in kg and age in years [26].
Questionnaire data
Trained health professionals used standardized question-
naires on socio-demographic characteristics and lifestyle
factors, such as tobacco, alcohol consumption and vita-
min intake. Participants were asked whether they were
taking vitamin supplements on a regular basis and if
yes, which type of vitamins. No specific information
allowing differentiating intakes of vitamin B6, B11 and
B12 was collected. For the purpose of the present ana-
lyses, smokers were defined as current smokers and
non-smokers as never- or ex-smokers. Alcohol con-
sumption was converted in standard units per day.
Genotyping and quality controls
Nuclear DNA was extracted from whole blood for entire
genome scan analysis. Genotyping was performed using
the Affymetrix 500 K chip, as recommended by the
manufacturer. Individuals with less than 95% genotyping
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efficiency overall (or < 90% efficiency on either array, n
= 399), and individuals with possible gender inconsisten-
cies (n = 5), were removed. Monomorphic single
nucleotide polymorphisms (SNPs), SNPs with less than
70% genotyping efficiency, SNPs with minor allele fre-
quency < 2% and SNPs not in Hardy-Weinberg propor-
tions were excluded from analyses, leaving at the end
4155 participants for the present genetic analysis. We
analyzed the 38 genotyped SNPs located within and
around (500 kb) the MTHFR gene for association with
tHcy, using multiple linear regression. Because of its
known clinical interest, the functional non-synonymous
MTHFR C677T polymorphism (rs1801133) [27] was also
included in the analysis, even though it was only
imputed. Imputation was done based on HapMap Phase
II haplotypes using the IMPUTE software, as previously
described [28]. Three of the genotyped SNPs were
strongly associated with tHcy levels (rs9651118, R2 =
0.51%, P = 2 × 10-7 ; rs1321073, R2 = 0.45%, P = 7 × 10-
7 and rs34175640, R2 = 0.45%, P = 7 × 10-7), as was the
imputed C677T polymorphism (rs1801133, R2 = 0.57%,
P = 9 × 10-7). Out of the three genotyped SNPs, two
were in perfect linkage disequilibrium (rs1321073 and
rs34175640), leaving only three partially independent
SNPs for the present analysis: rs1321073, rs9651118 and
rs1801133.
Statistical analyses
Statistical analyses were performed using Stata 10.0
(Stata Corp, College Station, USA). Results were
expressed as mean ± standard deviation (sd), median ±
interquartile range or median ± standard error (se). For
comparison of data between groups, we used a t-test for
continuous variables and a chi square test for dichoto-
mous variables. We used a non parametric test (nptrend
in Stata) to test for linear trend across selected cate-
gories whenever appropriate. We analyzed the associa-
tion between tHcy and SUA using a spearman rank
correlation test. For descriptive purposes, we split tHcy
into 4 categories (tHcy < 9, 9 ≤ tHcy < 12, 12 ≤ tHcy <
15, and tHcy ≥ 15 μmol/L), as previously published [1].
MDRD was dichotomized into < 90, and ≥ 90 mL/min/
1.73 m2 categories. We used median regression to ana-
lyze the association of MDRD with tHcy (dependent
variable), while adjusting for the potential confounding
effect or effect modification of selected covariates. A P-
value < 0.05 was considered as statistically significant
for mean effects. We systematically tested all two-way
interactions of MDRD with all other covariates in the
model. We used a Bonferroni-corrected P-value to select
which interaction terms to keep in the model (e.g. if 10
interaction terms were tested, we used 0.005 as a cut-off
P-value, etc). To keep the models hierarchically sound,
covariates included in a significant interaction term
were kept as main effects in the model. To ease inter-
pretation of the significant interaction terms on tHcy,
we also conducted stratified analyses by age (below vs
above the mean age of 53 years) and by serum uric acid
strata (below vs above the mean level of 321 μmol/L).
We used multiple logistic regression to analyze the asso-
ciation of hyperhomocysteinemia with dichotomized
albuminuria. We systematically tested all two-way inter-
actions between hyperhomocysteinemia or sex, on the
one side, and all other covariates in the model, on the
other side, and used a Bonferroni-corrected P-value to
select interaction terms to be kept in the model. We
analyzed the association of the SNPs with albuminuria
using logistic regression with an additive mode of
action. The corresponding P-values are not adjusted for
multiple testing.
Results
Among the 5913 participants aged 35-75 years, with a
mean (± sd) age at 53 years (± 11 years), 52.5% were
females. Table 1 displays participants’ characteristics
stratified by sex. Men were significantly younger than
women, reported higher alcohol consumption and lower
intake of B vitamins. Men had higher body mass index
(BMI), blood pressure, Modification of Diet in Renal
Disease (MDRD, estimation of GFR), fasting plasma glu-
cose, and SUA levels. Men also had a higher prevalence
of type 2 diabetes, smoking, hypertension and albumi-
nuria than women. Women had significantly lower tHcy
levels (9.3 (2.7) μmol/L vs. 10.9 (3.1) μmol/L, P < 0.001)
and prevalence of hyperhomocysteinemia (4.13% vs.
10.7%, P < 0.001) than men. tHcy levels were positively
correlated with SUA in men (r = 0.246, P < 0.001) and
in women (r = 0.287, P < 0.001).
In multiple regression analysis using tHcy as the
dependent variable, the association of MDRD with tHcy
was modified by age and SUA (Table 2, P for interaction
< 0.001) after adjusting for major confounding factors.
When conducting stratified analyses, the regression
coefficient for MDRD on tHcy was -0.043 [95%CI:
-0.050; -0.036] and -0.060 [-0.066; -0.054] in the younger
and older age groups, respectively, and -0.042 [95%CI:
-0.048; -0.036] and -0.057 [-0.064; -0.049] for the low
and high uric acid groups, respectively. To ease the
interpretation of these findings, Figure 1 shows the
adjusted median tHcy levels by MDRD and age groups.
Within each group, tHcy was more elevated in the high
SUA category than in the low SUA category. Sensitivity
analyses using the Cockcroft-Gault formula led to simi-
lar results.
In multiple logistic regression, hyperhomocysteinemia
(tHcy ≥ 15 μmol/L) (OR = 2.22, 95% confidence interval
(CI): 1.60-3.08, P < 0.001) and SUA (OR = 1.27, 95%CI:
1.08-1.50, per 100 μmol/L P = 0.004) were significantly
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related with albuminuria independently of hypertension
and diabetes (Table 3). The risk of albuminuria asso-
ciated with hyperhomocysteinemia (OR = 2.22, 95%CI:
1.60-3.08, P < 0.001) was similar to that associated with
hypertension (OR = 1.52, 95%CI: 1.11-2.09, P = 0.009)
or with type 2 diabetes (OR = 1.93, 95%CI: 1.27-2.91, P
= 0.002). We found no significant interaction between
hyperhomocysteinemia and any of the covariate in the
model, including SUA. Further adjustment for ACE
inhibitor and angiotensin receptor blocker treatment did
not substantially modify the association of hyperhomo-
cysteinemia with albuminuria (OR = 2.18, 95%CI: 1.57-
3.04), while decreasing the association of hypertension
with albuminuria (OR = 1.39; 95%CI: 0.99-1.96).
The prevalence of albuminuria was gradually higher
across increasing tHcy categories (Figure 2). A similar
trend was observed in subjects with normal GFR levels
(6.4%, 4.6%, 9.7% and 17.3%, P for trend < 0.005) and in
subjects with decreased GFR levels (3.5%, 5.0%, 8.3%
and 14.5%, P for trend < 0.005). Results were similar in
men and in women (data not shown).
In the subsample of the study population in which
genotyping was performed, we analyzed the association
of three MTHFR polymorphisms related to tHcy levels
with albuminuria (Figure 3). After adjustment for major
confounding factors, the risk of albuminuria increased
significantly from the AA to the GG genotype (OR =
1.28, 95%CI: 1.04-1.58 per G allele, P = 0.021) for the
rs1321073 SNP. A similar trend was observed for
Table 1 Participants’ characteristics by sex
Characteristics Men
(n = 2766)
Women
(n = 3147)
Age (years) 52.4 (10.7) 53.4 (10.7)
Alcohol consumption (units/day) 1.49 (1.57) 0.57 (0.80)
Smokers (%) 28.3 24.9
Intake of B vitamins (%) 5.8 8.9
Use of diuretics (%) 6.9 6.4
Body mass index (kg/m2) 26.6 (4.0) 25.1 (4.8)
Type 2 diabetes (%) 9.2 3.5
Hypertension (%) 41.5 29.8
Systolic blood pressure (mmHg) 132.0 (16.5) 124.7 (18.2)
Diastolic blood pressure (mmHg) 81.2 (10.7) 77.5 (10.5)
Hyperhomocysteinemia (%) 10.7 4.13
Serum measurements
Total homocysteine (μmol/L) 10.9 (3.1) 9.27 (2.7)
Creatinine (μmol/L) 88.1 (15.6) 72.0 (11.6)
MDRD c (ml/min/1.73 m2) b 85.9 (20.0) 79.3 (18.6)
Uric acid (μmol/L) 360.4 (74.8) 269.9 (66.4)
Total cholesterol (mmol/L) 5.56 (1.04) 5.61 (1.03)
HDL-cholesterol (mmol/L) 1.44 (0.36) 1.81 (0.42)
Fasting glucose (mmol/L) 5.78 (1.23) 5.34 (0.99)
Urine measurements
Albumin to creatinine ratio (mg/g) a 4.56 (5.26) 5.58 (5.88)
Albuminuria c (%) 6.9 5.4
Data are expressed as mean (standard deviation), n (%) or median a
(interquartile range).
b Modification of Diet in Renal Disease, estimation of glomerular filtration rate
c urinary albumin-to-creatinine ratio > 30 mg/g
Table 2 Determinants of total serum homocysteine
b-Coefficient 95% CI d
Sex (0 = men, 1 = women) -1.341 -1.540 -1.141 e
Age (years) 0.136 0.097 0.176 e
Alcohol consumption (units/day) 0.098 0.034 0.162 e
Smoking status 0.468 0.291 0.645 e
Intake of B vitamins -0.616 -0.904 -0.328 e
Use of diuretics 0.394 0.072 0.716 e
Body mass index (kg/m2) -0.019 -0.038 0.001
Systolic blood pressure (mmHg) 0.006 0.001 0.011 e
Total serum cholesterol (mmol/L) 0.030 -0.046 0.105
Plasma fasting glucose (mmol/L) -0.023 -0.096 0.050
Serum uric acid (μmol/L) 0.014 0.009 0.019 e
MDRD a (ml/min/1.73 m2) 0.037 0.010 0.064 e
MDRD × age b -0.0010 -0.0015 -0.0006 e
MDRD × uric acid c -0.00011 -0.00016 -0.00005 e
a Modification of Diet in Renal Disease, estimation of glomerular filtration rate
b Interaction between MDRD and age
c Interaction between MDRD and serum uric acid
d 95% Confidence Interval
e P value < 0.05
7.0
8.0
9.0
10.0
11.0
12.0
age < 55 y age >= 55 y age < 55 y age >=  55 y
MDRD < 90
ml/min/1.73 m
MDRD >= 90
ml/min/1.73 m
Total serum homocysteine  
(Pmol/L)
low uric acid
high uric acid
n=916
n=871
n=1115
n=1183
n=568
n=609
n=362
n=289
2 2
Figure 1 Total serum homocysteine levels by categories of
MDRD, age and uric acid levels. Bars (whiskers) are medians (se)
adjusted for sex, categories of age, MDRD and serum uric acid
levels. P-values for age, MDRD and serum uric acid categories <
0.001 from a multiple median regression using total serum
homocysteine as the dependent variable. MDRD, Modification of
Diet in Renal Disease, estimation of glomerular filtration rate.
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rs1801133 (OR = 1.20, 95%CI: 0.99-1.46 per T allele, P =
0.068), but the association was not significant for
rs9651118 (OR = 1.12, 95%CI: 0.89-1.42 per T allele, P
= 0.344). In non-diabetic subjects, the association
between albuminuria and both rs1321073 (OR = 1.31,
95%CI: 1.04-1.64 per G allele, P = 0.023) and rs1801133
(OR = 1.30, 95%CI: 1.05-1.61 per T allele, P = 0.017)
was significant. A similar trend was observed for
rs9651118 (OR = 1.11, 95%CI: 0.86-1.45 per T allele, P
= 0.417), although not reaching significance. In type 2
diabetic subjects, these polymorphisms were associated
neither with tHcy nor with albuminuria.
Discussion
In this large population-based study, the association
between elevated tHcy levels and higher prevalence of
albuminuria was observed independently of GFR, reflect-
ing the fact that this association is not simply the
consequence of reduced renal function. This result is
consistent with the hypothesis that homocysteine may
cause renal damage. We extend previous population-
based findings [1,10,11] to the age group 35-40 years.
Also, the association of hyperhomocysteinemia with
albuminuria was independent of hypertension, type 2
diabetes and uric acid levels. Furthermore, hyperhomo-
cysteinemia was associated with a 2-fold higher risk of
albuminuria, which was of similar magnitude to the risk
of albuminuria associated with hypertension or type 2
diabetes. This result strongly suggests that hyperhomo-
cysteinemia is an independent marker of renal dysfunc-
tion and is in line with the role of homocysteine as
potential atherogenic agent and cardiovascular risk fac-
tor [2].
We observed strong associations between homocys-
teine levels and MTHFR polymorphisms, as previously
reported [29-31]. This suggests that MTHFR genotypes
related to higher homocysteine levels are associated
with albuminuria in the general population, in particu-
lar in non-diabetic subjects. Because of the random
assortment of alleles at the time of gamete formation,
association between MTHFR genotypes and tHcy
levels, or albuminuria, should not be biased by reverse-
causality or major confounding factors. These results
therefore suggest that homocysteine might be causally
involved in renal damage. MTHFR polymorphisms
have been shown to be associated with increased mor-
tality and morbidity in healthy and CKD populations
[29-31]. Some studies in diabetic patients found the
C677T polymorphism (rs1801133) to be associated
with renal damage [32-36], but others failed to find
such association [37,38]. In this study, rs1321073 was
significantly associated with the risk of albuminuria in
the general population, independently of major con-
founding factors. However, this latter association was
not significant in type 2 diabetic subjects, in whom no
association with tHcy was observed. First of all, the
Table 3 Determinants of albuminuria
Albuminuria a Odds Ratio 95% CI c P-values
Smoking status (1 = current smoker, 0 = non-smoker) 1.35 1.05 - 1.74 0.018
Intake of B vitamins (1 = intake, 0 = no intake) 1.09 0.70 - 1.69 0.700
MDRD b (ml/min/1.73 m2) 1.005 0.997 - 1.013 0.219
Type 2 diabetes 1.93 1.27 - 2.91 0.002
Fasting glucose (mmol/L) 1.22 1.12 - 1.33 < 0.001
Hypertension 1.52 1.11 - 2.09 0.009
Systolic blood pressure (mm Hg) 1.01 1.01 - 1.02 < 0.001
Serum uric acid (per 100 μmol/L) 1.27 1.08 - 1.50 0.004
Hyperhomocysteinemia 2.22 1.60 - 3.08 < 0.001
Logistic regression model including age, sex, body mass index and age × sex interaction as additional covariates.
a urinary albumin-to-creatinine ratio > 30 mg/g
b Modification of Diet in Renal Disease, estimation of glomerular filtration rate
c 95% Confidence Interval
Prevalence of 
albuminuria (%)
MDRD >= 90 
ml/min/1.73 m
< 9 9-12 12-15 >=15
MDRD < 90 
ml/min/1.73 m2 2
0
2
4
6
8
10
12
14
16
18
20
n=1451
n=1598
n=690
n=346
n=970
n=581
n=196
n=81
P trend < 0.005P trend < 0.005
Total serum homocysteine categories
< 9 9-12 12-15 >=15
Total serum homocysteine categories
Figure 2 Prevalence (95%CI) of albuminuria by categories of
MDRD and total serum homocysteine. Results were similar in
men and in women. We assessed trend across total serum
homocysteine categories using non-parametric test. MDRD,
Modification of Diet in Renal Disease, used to estimate glomerular
filtration rate.
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number of diabetics was small. Second, since diabetes
itself represents a major cause of albuminuria, the
effect of homocysteine on renal damage might not be
easily detectable in this subgroup, as reflected by the
conflicting results reported in studies restricted to dia-
betic patients [32-38]. Results for the nonsynonymous
rs1801133 (C677T) SNP, which is associated with
reduced MTHFR activity [27], were quite similar.
Although associated with tHcy levels, rs9651118 was
not significantly associated with albuminuria, but the
effect was nevertheless in the same direction. As each
SNP only explained a tiny fraction of homocysteine
variance, this study might have reduced power to
detect this association.
   0
8.5
9.0
9.5
10.0
10.5
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
rs1321073 rs1801133 rs9651118
Total serum 
homocysteine
(Pmol/l)
CC CT TT
Odds ratio
(95% CI)
AA AG GG
G allele T allele
Additive risk allele
T allele
P < 0.001 P < 0.001A.
B.
P < 0.001
rs1321073 rs1801133 rs9651118
P = 0.021 P = 0.068 P = 0.344
412
1730
2013
CC CT TT
1712
1980
463
166
1344
2645
Figure 3 Adjusted Odds Ratios (OR) for the risk of albuminuria by MTHFR gene polymorphisms. Genetic analysis was performed in a
subgroup of study (n = 4155). OR were adjusted for age, sex, smoking, alcohol consumption, intake of vitamin B, body mass index,
hypertension, systolic blood pressure, type 2 diabetes, plasma fasting glucose, total cholesterol, serum uric acid and glomerular filtration rate. A.
Median unadjusted total serum homocysteine level by genotype for each MTHFR polymorphism.B. Adjusted odds ratio for the risk of
albuminuria per risk allele (additive model).
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In line with previous reports, we found a positive
association between SUA and tHcy [19]. However, SUA
did not modify the relationship between tHcy levels and
albuminuria. This suggests that there is no strong syner-
gistic or antagonistic effect between homocysteine and
uric acid for their effect on renal damage, but rather
that both factors act independently on albuminuria.
Conversely, we observed an effect modification of uric
acid on the known negative association between tHcy
levels and GFR, independently of major confounding
factors. We are not aware that the effect modification of
SUA on the association between tHcy and renal func-
tion has been previously reported. Both hyperuricemia
and hyperhomocysteinemia are common findings in
patients with CKD. In prospective studies among CKD
patients, baseline SUA and baseline tHcy levels appeared
to predict overall mortality [4,18]. However the link
between tHcy, SUA and decreased renal function is
unclear. A possible explanation is that antioxidants, like
uric acid, raise in reaction to increased oxidative stress
to counteract the harmful effect of reactive oxygen spe-
cies induced by elevated homocysteine [8]. Reactive oxy-
gen species reduce glomerular blood flow and filtration
rate by release of vasoconstrictors and, possibly by inac-
tivation of NO [39].
Hyperhomocysteinemia is frequent in patients with
CKD [1,4]. In this study, tHcy was higher whenever
renal function was decreased. This might result, in part,
from the fact that impaired renal function reduces the
renal clearance of homocysteine. This could also result,
in part, from impaired intrarenal homocysteine metabo-
lism, impaired extrarenal homocysteine metabolism or
both. Also the prevalence of albuminuria was gradually
higher with increasing tHcy levels, independently of glo-
merular filtration rate, since a similar trend was
observed after stratifying for normal and decreased GFR
levels. Several prospective studies have shown that
hyperhomocysteinemia is an independent determinant
of the development of CKD and albuminuria in the gen-
eral population [11,40]. Moreover, in a prospective
study, kidney transplant recipients with elevated tHcy
levels at baseline had a greater risk of death and kidney
allograft loss [4]. These findings further support the
concept that tHcy is not merely a marker, but rather a
predictor of CVD. CVD currently represents the main
cause of death in CKD patients, with mortality rates
three to 30 times higher than expected [6,41]. As this
high mortality is only partly explained by CVD risk fac-
tors, such as hypertension, diabetes, smoking and dysli-
pidemia, factors such as hyperhomocysteinemia and
elevated uric acid levels may play a role.
Our study has several limitations. Unfortunately, we
have no data on vitamin status, including folic acid, vita-
min B6, and vitamin B12, but we could include data on
reported vitamin B intake. However, several previous stu-
dies observed no significant interaction of vitamin B sta-
tus on the association between tHcy and renal function
or tHcy and cardiovascular risk [1,42]. We used estima-
tions of GFR by the MDRD formula in this study. As
MDRD has not been validated in populations with nor-
mal GFR, we also conducted sensitivity analyses using
GFR estimated by the Cockcroft-Gault formula, which
led to similar results. The calculated GFR and albumin-
to-creatinine ratio (ACR) were based on a single mea-
surement, as in previous population-based studies [1,10].
tHcy was also based on one single measure and is there-
fore insufficient to predict life-time exposure. Despite the
small proportion of homocysteine variance explained,
MTHFR polymorphisms may better reflect the life-time
exposure to tHcy. However, our study also has several
strengths. It is to our knowledge the largest population-
based study exploring associations between homocysteine
and renal function, hence with a wide external validity. A
longitudinal follow-up of all participants in the CoLaus
study is currently ongoing and shall provide essential
data for trends over time of major cardiovascular risk fac-
tors according to baseline homocysteine levels.
Conclusions
In conclusion, hyperhomocysteinemia was associated
with higher prevalence of albuminuria in men and in
women, independently of renal function. The association
of hyperhomocysteinemia with albuminuria was not only
independent of type 2 diabetes and hypertension, but
also as strong as the one found for these two conditions,
which are major causes of albuminuria. Individuals car-
rying MTHFR genotypes associated with higher tHcy
concentrations were at increased risk for albuminuria.
This latter finding supports the hypothesis that homo-
cysteine causes renal damage. Further studies are needed
to explore whether lowering serum homocysteine levels
might prevent kidney damage. Serum uric acid was also
associated with albuminuria, independently of homocys-
teine. Although uric acid modified the association of
tHcy with GFR, no such effect modification was
observed for the association between hyperhomocystei-
nemia and albuminuria, which speaks against a strong
synergistic or antagonistic effect between homocysteine
and uric acid on renal damage.
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